Depemokimab Reduced Asthma Exacerbations in 2026 Trials
A pooled analysis showed the drug effectively lowered exacerbation rates in patients with type 2 asthma.
Updated on Oct. 2, 2026 in Asthma
Live Poll
Do you trust that less frequent dosing for chronic conditions provides the same health benefits?
In 2026, clinical trials demonstrated that depemokimab reduced the probability of asthma exacerbations by 46 percent over a 52-week period. The treatment, which requires only twice-yearly dosing, showed efficacy as early as four weeks after the first injection.
Why it matters
Patients living with uncontrolled type 2 asthma often face unpredictable and frequent breathing crises. This therapy provides an alternative treatment option that simplifies the administration schedule compared to standard daily or monthly regimens.
The SWIFT-1 and SWIFT-2 trials included 762 participants who received 100 mg doses of depemokimab. Significant reductions were observed in specific subgroups, including a 72 percent decrease for those with asthma duration under 10 years.
The players
National Jewish Health
This institution is a leading respiratory hospital and research center where the lead study author is affiliated.
The details
Researchers conducted a pooled analysis of 762 patients who were randomly assigned to receive either 100 mg of depemokimab or a placebo via subcutaneous injection at weeks 0 and 26. The results indicated that the drug effectively lowered exacerbation rates across multiple patient profiles, including those with chronic rhinosinusitis with nasal polyps.
Timeline
Week 0 was when patients received their initial 100 mg dose.
Week 4 marked the point at which treatment efficacy became observable.
Week 26 was when patients received their second dose of treatment.
52 weeks was the total study duration for measuring exacerbation rates.
The Big Picture
This story reports the pooled outcomes of the phase 3 SWIFT-1 and SWIFT-2 trials. These trials represent a critical step in testing new biological interventions for managing severe asthma.
The study suggests that patients may eventually benefit from a significantly reduced treatment schedule of only two injections per year. This shift could help individuals with uncontrolled asthma better manage their condition with fewer disruptions to daily routines.
The takeaway
The study highlights that biological therapies may offer high-efficacy alternatives for patients struggling with standard inhaled corticosteroids. Individuals should consult with their healthcare provider to discuss how these new treatment options compare to existing management plans.
Further reading
For more information on current treatment trends, visit the Asthma section.
Source note: This article includes information reported by Ajmc.
Live Poll
Do you trust that less frequent dosing for chronic conditions provides the same health benefits?
